Overview

• Studies reveal that IDO1 inhibitors, originally developed for cancer, can improve brain energy metabolism in Alzheimer's models.
• Blocking IDO1 activity in mice restored memory and cognitive function, showing potential for human treatment.
• The drug PF06840003 successfully crossed the blood-brain barrier and improved glucose metabolism in astrocytes.
• Research indicates that targeting brain metabolism could be effective for multiple neurodegenerative diseases.
• Human trials are needed to confirm these promising findings from preclinical studies.